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MicroRNAs (miRNAs) are small 21-25 nucleotide RNA 
molecules  that  comprise  an  evolutionarily  conserved 
class of ribo-regulators which modulate gene expression 
via the RNA interference pathway. Initially considered a 
peculiarity  of  nematodes  it  is  now  known  that  these 
small  non  protein  coding  RNAs  also  occur  in  a  wide 
variety  of  other  organisms  like  plants,  arthropods  and 
vertebrates  such  as  amphibians,  birds,  fish  and  mam-
mals. Often their sequences and spatial/temporal expres-
sion patterns are conserved. Currently 4039 entries have 
been  made  in  the  miRNA  registry,  version  8.2 
(http://microrna.sanger.ac.uk)  including  462  human 
miRNAs that can be classified into several families of 
related miRNAs. It is estimated that there are as many as 
a thousand miRNA genes in the mammalian genome that 
regulate  one-third  of  the protein coding  genes.  Hence, 
there  will  be  very  few  cellular  processes  that  are  not 
affected by miRNAs.  
 
miRNA  genes  are  transcribed  by  RNA  polymerase  II 
forming long (up to several  kb) primary  miRNAs that 
are  capped  and  polyadenylated.  The  pri-miRNAs  fold 
into a stem-loop structure and are converted to their ma-
ture forms in two sequential processing steps by a nu-
clear (Drosha) and a cytoplasmic (Dicer) RNase III en-
donuclease. The miRNAs function within large protein 
complexes  (RNA  induced  silencing  complex/RISC)  to 
negatively regulate specific target mRNAs. They do so 
by base-pairing with their target sequence - often in the 
3’ UTR of mRNAs – which results in translational re-
pression  or  mRNA  degradation.  Contrary  to  plants, in 
animals most miRNAs have an imprecise complementar-
ity to their target sequences. Computational algorithms 
aimed  at  identifying  mRNA  targets  indicate  that  most 
miRNAs have multiple targets ranging from dozens to 
hundreds and that each target mRNAs may bind multiple 
miRNAs.  
 
miRNAs have been implicated  in  the control  of  many 
fundamental cellular and physiological processes such as 
developmental timing, cell differentiation, cell prolifera-
tion, apoptosis and stem cell division. However the pre-
cise  function  of  most  miRNAs  is  still  unknown  as  is 
their involvement in diseases like cancer. Enhanced pro-
liferation and dysregulated cell death are important can-
cer  cell  characteristics.  Notably  several  of  the  first 
miRNAs  described  in  Caenorhabditis  elegans  (lin-4) 
and  Drosophila  (bantam,  miR-14,  miR-2/6/11/13/308) 
were  shown  to  affect  just  these  cancer  relevant  path-
ways.  Moreover, a study  in which 90  different  human 
miRNAs were down-regulated by antisense oligonucleo-
tides  demonstrated  that  multiple  miRNAs  affect  cell 
proliferation and apoptosis in cervical (Hela) and lung 
(A549) carcinoma cells.  In  addition,  it was found that 
miRNA genes are frequently found in genomic regions 
and fragile sites associated with cancer and that the ex-
pression  of  many  miRNAs  is  dysregulated  in  clinical 
cancer samples (Zhang et al, 2006). Calin et al were the 
first to report that miRNAs may function as tumor sup-
pressors. It was shown that the cluster of miR-15a and 
16-1 genes, localized on chromosome 13q14, was found 
to be deleted or down-regulated in more than 65% of B-
cell  chronic  lymphatic  leukemia  (B-CLL)  patients,  in 
50%  of  mantle  cell  lymphomas,  16-40%  of  multiple 
myeloma and 60% of prostate cancer (Calin et al, 2002). 
Also,  miR-143  and  miR-145  whose  expression  is  re-
duced in colorectal cancers, and let-7 family  members 
that  were  found  to  be  down-regulated  in  lung  cancer, 
may have a tumor suppressing role. A reduced let-7 ex-
pression in lung cancer was found to be associated with 
shorter  post-operative  survival.  Alternatively,  an  up-
regulation of miR-155/BIC was detected in breast can-
cer,  diffuse  large  B-cell  lymphoma  and  several  other 
hematological  malignancies.  A  significant  over-
expression  of  miR-197  and  miR-346  was  observed  in 
follicular  thyroid  carcinoma,  miR-221,  miR-222  and 
miR-146  were  found  up-regulated  in  papillary  thyroid 
carcinoma and a polycistronic miRNA cluster miR-17-
92  is  over-expressed  in  lung  cancers  and  B-cell  lym-
phomas.  Further  studies  provided  experimental  proof  
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implicating the miR-17-92 cluster as potential oncogene 
because  over-expression  of  the  cluster  accelerated  c-
MYC  induced  tumor  development  in  a  mouse  B-cell 
lymphoma model (He et al, 2005).  
 
Up till now very limited information is available about the 
physiological mRNA targets recognized by the miRNAs 
that are aberrantly expressed in cancers. miR-15a and miR-
16-1 may induce apoptosis by targeting the anti-apoptotic 
BCL2, let-7 targets the critical oncogene RAS and miR-
17-5p and miR-20a, that belong to the miR-17-92 cluster, 
negatively regulate the translation of the MYC target gene 
E2F1. Interestingly, the expression of the miR-17-92 clus-
ter itself is induced by the MYC oncogene, suggesting the 
existence of complex genetic connections controlling cel-
lular proliferation (O’Donnell et al, 2005). 
 
Clearly,  we  are  only  just  beginning  to  understand  the 
role of miRNAs and the extent to which they contribute 
to carcinogenesis and other disorders. Of direct clinical 
value are the findings  that  miRNA expression profiles 
can be used to classify cancers, even better so than regu-
lar mRNA expression profiling involving thousands of 
genes.  From  these  profiling  studies  one  may  identify 
prognostic miRNA signatures that may be used for diag-
nostic purposes (Yanaihara et al, 2006). Equally intrigu-
ing is the possibility to therapeutically intervene through 
the over-expression or silencing of specific miRNAs. It 
was shown that endogenous miRNAs in mice were effi-
ciently and specifically silenced by intravenous injection 
of  chemically  modified,  cholesterol-conjugated,  single 
stranded  RNA  analogs  complementary  to  the  mature 
miRNAs (antagomirs) (Krützfeldt et al, 2005). A silenc-
ing  effect  could  be  observed  in  all  tissues  except  the 
brain for prolonged periods of time. As miRNA research 
gains  speed  we  will  soon  learn  more  about  this  new 
regulatory layer of gene expression. 
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